LOGIN  |  REGISTER
Astria Therapeutics

Owens & Minor to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference

March 01, 2023 | Last Trade: US$8.13 0.03 -0.37

RICHMOND, Va. / Mar 01, 2023 / Business Wire / Owens & Minor, Inc. (NYSE: OMI) announced today that executive leadership will participate in a fireside chat at the upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference. The discussion will take place on Thursday, March 2 at 8:45 a.m. Eastern Time.

Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-presentations/ at least ten minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.

About Owens & Minor

Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home. Owens & Minor drives visibility, control and efficiency for patients, providers and healthcare professionals across the supply chain with proprietary technology and solutions, an extensive product portfolio, an Americas-based manufacturing footprint for personal protective equipment (PPE) and surgical products, as well as a robust portfolio of products and services for patients managing chronic and acute conditions in the home setting. Operating continuously since 1882 from its headquarters in Richmond, Va., Owens & Minor is a 140-year-old company powered by more than 20,000 global teammates. Learn more at https://www.owens-minor.com, follow @Owens_Minor on Twitter and connect on LinkedIn at www.linkedin.com/company/owens-&-minor.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page